Bifunctional quinolinonyl DKA derivatives were first described as nonselective inhibitors of 3'-processing (3'-P) and strand transfer (ST) functions of HIV-1 integrase (IN), while 7-aminosubstituted quinolinonyl derivatives were proven IN strand transfer inhibitors (INSTIs) that also displayed activity against ribonuclease H (RNase H). In this study, we describe the design, synthesis, and biological evaluation of new quinolinonyl diketo acid (DKA) derivatives characterized by variously substituted alkylating groups on the nitrogen atom of the quinolinone ring. Removal of the second DKA branch of bifunctional DKAs, and the amino group in position 7 of quinolinone ring combined with a fine-tuning of the substituents on the benzyl group in position 1 of the quinolinone, increased selectivity for IN ST activity. In vitro, the most potent compound was 11j (IC50 = 10 nM), while the most active compounds against HIV infected cells were ester derivatives 10j and 10l. In general, the activity against RNase H was negligible, with only a few compounds active at concentrations higher than 10 μM. The binding mode of the most potent IN inhibitor 11j within the IN catalytic core domain (CCD) is described as well as its binding mode within the RNase H catalytic site to rationalize its selectivity.
Bifunctional pan class="Chemical">quinolinonyl DKA derivatives were first described as nonselective class="Chemical">pan class="Gene">inhibitors of 3'-processing (3'-P) and strand transfer (ST) functions of HIV-1integrase (IN), while 7-aminosubstituted quinolinonyl derivatives were proven IN strand transfer inhibitors (INSTIs) that also displayed activity against ribonuclease H (RNase H). In this study, we describe the design, synthesis, and biological evaluation of new quinolinonyl diketo acid (DKA) derivatives characterized by variously substituted alkylating groups on the nitrogen atom of the quinolinone ring. Removal of the second DKA branch of bifunctional DKAs, and the amino group in position 7 of quinolinone ring combined with a fine-tuning of the substituents on the benzyl group in position 1 of the quinolinone, increased selectivity for IN ST activity. In vitro, the most potent compound was 11j (IC50 = 10 nM), while the most active compounds against HIV infected cells were ester derivatives 10j and 10l. In general, the activity against RNase H was negligible, with only a few compounds active at concentrations higher than 10 μM. The binding mode of the most potent INinhibitor 11j within the IN catalytic core domain (CCD) is described as well as its binding mode within the RNase H catalytic site to rationalize its selectivity.
Authors: V R de Soultrait; Pierre Yves Lozach; Ralf Altmeyer; L Tarrago-Litvak; S Litvak; M L Andréola Journal: J Mol Biol Date: 2002-11-22 Impact factor: 5.469
Authors: Arpita Agrawal; Jamie DeSoto; Jessica L Fullagar; Kasthuraiah Maddali; Shahrzad Rostami; Douglas D Richman; Yves Pommier; Seth M Cohen Journal: Proc Natl Acad Sci U S A Date: 2012-01-27 Impact factor: 11.205
Authors: Laura De Luca; Sara De Grazia; Stefania Ferro; Rosaria Gitto; Frauke Christ; Zeger Debyser; Alba Chimirri Journal: Eur J Med Chem Date: 2010-12-21 Impact factor: 6.514
Authors: Beatriz Grinsztejn; Bach-Yen Nguyen; Christine Katlama; Jose M Gatell; Adriano Lazzarin; Daniel Vittecoq; Charles J Gonzalez; Joshua Chen; Charlotte M Harvey; Robin D Isaacs Journal: Lancet Date: 2007-04-14 Impact factor: 79.321
Authors: Christophe Marchand; John A Beutler; Antony Wamiru; Scott Budihas; Ute Möllmann; Lothar Heinisch; John W Mellors; Stuart F Le Grice; Yves Pommier Journal: Antimicrob Agents Chemother Date: 2007-10-29 Impact factor: 5.191
Authors: Valentina Noemi Madia; Marta De Angelis; Daniela De Vita; Antonella Messore; Alessandro De Leo; Davide Ialongo; Valeria Tudino; Francesco Saccoliti; Giovanna De Chiara; Stefania Garzoli; Luigi Scipione; Anna Teresa Palamara; Roberto Di Santo; Lucia Nencioni; Roberta Costi Journal: Pharmaceuticals (Basel) Date: 2021-03-09